Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer

Published:2023-06 Issue:5 Volume:14 Page:101520
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Deol Ekamjit S.,Sanfilippo Kristen M.,Luo Suhong,Fiala Mark A.,Wildes Tanya,Mian Hira,Schoen Martin W.

Funder

Prostate Cancer Foundation

US Department of Defense Prostate Cancer Research Program

U.S. Department of Defense

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference41 articles.

1. Prostate cancer epidemiology;Grönberg;The Lancet,2003

2. NCI SEER Program Cancer Stat Facts: Prostate Cancer. Accessed December 2022. https://seer.cancer.gov/statfacts/html/prost.html.

3. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC);Henríquez;Biomedicines.,2021

4. Systematic review and network Meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer;McCool;Value Health J Int Soc Pharmacoecon Outcomes Res,2018

5. Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate cancer: a systematic review and indirect comparison;Zheng;Biomed Res Int,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing frailty from laboratory into real world: A critical step toward frailty‐guided clinical care of older adults;Journal of the American Geriatrics Society;2024-08-21

2. Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data;Drugs & Aging;2024-07

3. Influence of frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer;2024-06-20

4. Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide;Clinical Genitourinary Cancer;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3